Free Newsletter
SPOTLIGHT: Avandia cleared FDA by one vote
SPOTLIGHT ... Avandia cleared FDA by one vote
Behind closed doors, the FDA's safety board barely backed GlaxoSmithKline's Avandia last month, voting 8-to-7 to keep the drug on the market with tougher warnings of heart risks rather than pull it completely. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: